

Oncolytic Virus Therapy Market Analysis With opportunity segments

The Business Research Company has updated its global market reports with latest data for 2024 and projections up to 2033

LONDON, GREATER LONDON, UK, June 28, 2024 /EINPresswire.com/ -- The [global oncolytic virus therapy market](#) is projected to grow from \$0.15 billion in 2023 to \$0.19 billion in 2024, at a

compound annual growth rate (CAGR) of 26.2%. This growth is driven by advancements in genetic engineering, increased understanding of tumor microenvironments, clinical successes, and regulatory approvals. The market is expected to further expand to \$0.44 billion by 2028, growing at a CAGR of 23.9% fueled by the expansion of oncolytic virus platforms and synergistic combinations with immune checkpoint inhibitors.



You Can Now Pre Order
Your Report To Get A Swift
Deliver With All Your Needs”
*The Business Research
Company*

Rising Clinical Trials Propel Market Growth

The surge in ongoing clinical trials utilizing oncolytic virus therapy underscores its potential in selectively targeting cancer cells while preserving healthy tissue. As of October 2023, the number of registered studies globally increased significantly, highlighting the growing interest and

investment in this therapeutic approach.

Explore the global oncolytic virus therapy market with a detailed sample report:

https://www.thebusinessresearchcompany.com/sample_request?id=12391&type=smp

Key Players and Strategic Collaborations

Major players such as Pfizer Inc., Johnson & Johnson, and AstraZeneca PLC are leveraging strategic partnerships to enhance their capabilities in oncolytic virus therapy. For instance, RenovoRx Inc. and Imugene Ltd. have partnered to optimize delivery methods for oncolytic virus therapies, focusing on challenging-to-access tumors.

Emerging Trends in Virology and Immunology



Technological advancements in delivery systems and synthetic biology are driving innovation within the oncolytic virus therapy market. Collaborations and partnerships in the biopharmaceutical industry are facilitating rapid advancements in treatment modalities.

Market Segmentation

- Therapy Type: HSV-Based Oncolytic Virus Therapy, Adenovirus-Based Oncolytic Virus Therapy, Reovirus, Poxviruses, NDV (Newcastle Disease Virus), Other Therapy Types
- Virus Type: Genetically Engineered Oncolytic Viruses, Oncolytic Wild-Type Viruses
- Application: Breast Cancer, Lung Cancer, Prostate Cancer, Melanoma, Brain Tumor, Blood Cancer
- End-User: Hospitals, Specialty Clinics, Cancer Research Institutes

Geographical Insights: North America Leading the Market

North America dominated the oncolytic virus therapy market in 2023 and is poised to maintain its lead, driven by robust healthcare infrastructure and increasing R&D investments.

Make your report purchase here and explore the whole industry's data as well

<https://www.thebusinessresearchcompany.com/report/oncolytic-virus-therapy-global-market-report>

[Oncolytic Virus Therapy Global Market Report 2024](#) from TBRC covers the following information:

- Market size data for the forecast period: Historical and Future
- Market analysis by region: Asia-Pacific, China, Western Europe, Eastern Europe, North America, USA, South America, Middle East and Africa.
- Market analysis by countries: Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.

Trends, opportunities, strategies and so much more.

The Oncolytic Virus Therapy Global Market Report 2024 by The Business Research Company is the most comprehensive report that provides insights on oncolytic virus therapy market size, oncolytic virus therapy market drivers and trends, oncolytic virus therapy market major players, competitors' revenues, market positioning, and market growth across geographies. The oncolytic virus therapy market report helps you gain in-depth insights on opportunities and strategies. Companies can leverage the data in the report and tap into segments with the highest growth potential.

Browse Through More Similar Reports By The Business Research Company:

Cancer Vaccines Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/cancer-vaccine-global-market-report>

Anti-Cancer MAbS Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/anti-cancer-mabs-global-market-report>

Solid Tumor Cancer Treatment Global Market Report 2024

<https://www.thebusinessresearchcompany.com/report/solid-tumor-cancer-treatment-global-market-report>

[About The Business Research Company](#)

The Business Research Company has published over 27 industries, spanning over 8000+ markets and 60+ geographies. The reports draw on 1,500,000 datasets, extensive secondary research, and exclusive insights from interviews with industry leaders.

Global Market Model – Market Intelligence Database

The Global Market Model, The Business Research Company's flagship product, is a market intelligence platform covering various macroeconomic indicators and metrics across 60 geographies and 27 industries. The Global Market Model covers multi-layered datasets that help its users assess supply-demand gaps.

Contact Information

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 8897263534

Americas: +1 315 623 0293

Oliver Guirdham

The Business Research Company

+44 20 7193 0708

info@tbrc.info

Visit us on social media:

[Facebook](#)

[X](#)

[LinkedIn](#)

This press release can be viewed online at: <https://www.einpresswire.com/article/723660117>

EIN Presswire's priority is source transparency. We do not allow opaque clients, and our editors try to be careful about weeding out false and misleading content. As a user, if you see something we have missed, please do bring it to our attention. Your help is welcome. EIN Presswire, Everyone's Internet News Presswire™, tries to define some of the boundaries that are reasonable in today's world. Please see our Editorial Guidelines for more information.

© 1995-2024 Newsmatics Inc. All Right Reserved.